"Glucosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D005960
|
MeSH Number(s) |
D09.408.348
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucosides".
Below are MeSH descriptors whose meaning is more specific than "Glucosides".
This graph shows the total number of publications written about "Glucosides" by people in this website by year, and whether "Glucosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2007 | 0 | 1 | 1 |
2008 | 1 | 3 | 4 |
2011 | 2 | 0 | 2 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2015 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 1 | 1 | 2 |
2018 | 3 | 0 | 3 |
2019 | 2 | 1 | 3 |
2020 | 6 | 2 | 8 |
2021 | 4 | 3 | 7 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosides" by people in Profiles.
-
Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther. 2024 Feb; 38(1):1-3.
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
An in vivo and in vitro model on the protective effect of corilagin on doxorubicin-induced cardiotoxicity via regulation of apoptosis and PI3-K/AKT signaling pathways. J Biochem Mol Toxicol. 2021 Dec; 35(12):e22926.
-
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2022 10; 36(5):829-840.
-
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. Diabetes Obes Metab. 2021 06; 23(6):1426-1430.
-
Early eGFR decline after SGLT2i initiation: knowns and unknowns. Kidney Int. 2021 03; 99(3):548-550.
-
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Circulation. 2021 04 27; 143(17):1673-1686.
-
Dapagliflozin in Patients with Chronic Kidney Disease. Reply. N Engl J Med. 2021 01 28; 384(4):389-390.
-
In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. Ann Intern Med. 2020 11 17; 173(10):JC51.
-
Modular metabolite assembly in Caenorhabditis elegans depends on carboxylesterases and formation of lysosome-related organelles. Elife. 2020 10 16; 9.